News

Oncocyte Prepares for Financial Results Announcement Soon

Oncocyte Prepares for Financial Results Announcement Soon

Oncocyte Corp to Unveil Financial Results

Oncocyte Corp (NASDAQ: OCX), a leader in diagnostics technology, has made an exciting announcement regarding its upcoming third-quarter financial results for 2024. The results will be revealed on Tuesday, November 12, 2024, once the U.S. markets close. This event demonstrates the company’s commitment to transparency and keeping its investors informed about its financial health.

Conference Call Details

Directly following the release of the financial results, Oncocyte will host a conference call and webcast to delve into the highlights of its performance and answer questions from interested parties. This interactive session will take place at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day. Investors and stakeholders are encouraged to participate.

How to Join the Call

Participating in the conference call is simple. Domestic callers can dial the toll-free number 800-715-9871. By joining the call, participants can directly hear from the management team about the essential aspects of the company's financial results.

Accessing the Webcast

For those who prefer a visual format, the live webcast of the earnings call can be accessed through the ‘Events & Presentations’ section on the Oncocyte website. A recording of the webcast will be available shortly after the event for those unable to attend live.

Understanding Oncocyte’s Offerings

Oncocyte is known for its innovative diagnostics technology aimed at assisting healthcare providers in delivering better patient outcomes. The company’s product portfolio includes advanced blood-based tests designed to enhance clarity and confidence in post-transplant monitoring and immunotherapy responses.

Innovative Testing Solutions

Among its flagship products is VitaGraft™, a clinical blood test that monitors solid organ transplantation processes. This test plays a crucial role in enhancing patient care by providing healthcare professionals with vital information needed to manage organ transplants effectively.

Research and Development Focus

Additionally, GraftAssure™ serves as a research use-only (RUO) blood-based test aimed specifically at tracking the health of transplant patients. Oncocyte is also committed to innovation with its gene expression test, DetermaIO™, which evaluates the tumor microenvironment to predict how well a patient might respond to immunotherapies. This focus on research and new technologies showcases Oncocyte's dedication to improving cancer treatment outcomes.

Supporting Cancer Patients

Oncocyte continues to expand its product lineup, with tools like DetermaCNI™, which is a blood-based monitoring tool that assesses therapeutic efficacy in cancer patients. These testing solutions not only stand at the forefront of technology but also align with the company’s mission to empower healthcare professionals through actionable insights.

Company Vision

The driving vision behind Oncocyte is to provide clarity and confidence to physicians and their patients. By continually redefining diagnostic accuracy, the company plays a pivotal role in enhancing healthcare outcomes.

Final Thoughts

As the financial results announcement approaches, investors are eagerly awaiting insights that will shed light on the company's growth trajectory and future prospects. Oncocyte's commitment to innovation and patient care underpins its operational strategies, which position it well in the diagnostics market.

Frequently Asked Questions

1. What is the date for Oncocyte’s financial results release?

Oncocyte Corp will release its third-quarter financial results on November 12, 2024.

2. How can I participate in the conference call?

To join the conference call, dial 800-715-9871 for domestic calls and ask to be connected to the Oncocyte Corporation call.

3. Where can I find the webcast for the conference call?

The webcast can be accessed via the ‘Events & Presentations’ section of Oncocyte’s website.

4. What are some key products offered by Oncocyte?

Oncocyte’s key products include VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™.

5. What is the mission of Oncocyte?

Oncocyte aims to provide clarity and confidence to both physicians and patients through advanced diagnostic solutions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 304

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 211

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 201

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 272

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 296

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 138

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 238

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Robinhood Markets Shares November 2025 Operational Highlights

Updated Category News Views 269

Robinhood Markets Releases November 2025 Operational Highlights Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) has recently shared its monthly operating data for November 2025, offering an insightful look into its operational metrics and customer engagement. This report emphasizes key growth indicators and trading volume achievements over the month, reflecting...

Continue Reading
Gold Prices Decline Amid Anticipation of Federal Reserve Actions

Updated Category News Views 140

Gold Prices Drop as Federal Reserve Meeting Commences Gold prices experienced a decline as traders adjusted their positions ahead of the Federal Reserve's crucial meeting. The latest updates signal a decrease in spot gold prices, which now hover around $2,646.06 an ounce. Similarly, gold futures, set to expire in February, showed a minor drop to $2,662.44 an ounce. This...

Continue Reading
Understanding Adobe's Current Stock Performance Analysis

Updated Category News Views 239

Market Dynamics of Adobe Inc. Investors are taking a closer look at Adobe Inc (NASDAQ: ADBE) as they adopt varying strategies in the options market. Notably, deep-pocketed investors have shown bearish tendencies, making it a key point of interest for those monitoring market movements. Recent observations have highlighted an unusual upsurge in options activities related to...

Continue Reading
NexPoint Diversified Real Estate Trust's New Preferred Share Offering

Updated Category News Views 212

NexPoint Diversified Real Estate Trust Announces Major Offering NexPoint Diversified Real Estate Trust (NYSE: NXDT), a leading player in the real estate investment trust sector, has unveiled an opportunity for investors with a continuous public offering of its 9.00% Series B Cumulative Redeemable Preferred Shares. With a planned issuance of up to 16,000,000 shares, the...

Continue Reading
Outbrain Dominates the Q4 2024 France Ad Seller Rankings

Updated Category News Views 185

Outbrain Leads the Way in France's Q4 2024 Ad Rankings In a recent release, Pixalate has highlighted the leading programmatic ad sellers in France for the fourth quarter of 2024. This report emphasizes the importance of quality within the digital advertising ecosystem, offering a glimpse into the companies making significant strides in this sector. Understanding the...

Continue Reading